Cue Biopharma to present on CUE-401, CUE-100 series at conference

Cue Biopharma announced that members of its management team will deliver two presentations at The Promise of Interleukin-2 Therapy Conference, taking place September 4-7, 2024 in Paris, France. Presentation Title: CUE-401: A Novel IL-2/TGF-beta fusion protein for the induction & expansion of FOXP3+ regulatory T Cells: Dr. Quayle will present preclinical data on our first-in-class bispecific fusion protein, CUE-401, which induces and expands regulatory T cells through the co-delivery of interleukin 2 and transforming growth factor beta and how this approach differentiates from other Treg-directed therapies. Presentation title: Clinical safety and efficacy of TCR-specific engagers that selectively target IL-2 to tumor-specific T cells: Dr. Levisetti will discuss how the company’s lead oncology programs CUE-101 and CUE-102, representative of the CUE-100 series of Immuno-STAT biologics, enable selective targeting of the cytokine IL-2 to tumor specific T cells for enhanced efficacy and safety profiles.